Skip to main content
Clinical Trials/NCT06286462
NCT06286462
Active, not recruiting
Not Applicable

Implementing and Evaluating the Cancer Tracking System (CATSystem): A Systems Level Intervention to Improve Cervical Cancer Screening, Treatment Referral and Follow up in Kenya

University of Kansas Medical Center10 sites in 1 country6,600 target enrollmentFebruary 5, 2024

Overview

Phase
Not Applicable
Intervention
Cancer Tracking System (CATSystem)
Conditions
Cervical Cancer
Sponsor
University of Kansas Medical Center
Enrollment
6600
Locations
10
Primary Endpoint
Guideline adherent treatment for a positive screen
Status
Active, not recruiting
Last Updated
last month

Overview

Brief Summary

Cervical cancer contributes to significant preventable mortality in Kenya where less than 20% of women are screened. The Cancer Tracking System (CATSystem) is a web-based, algorithm generated tool to promote guideline adherent cervical cancer screening and retention through treatment. The goal of this project is to rigorously evaluate the efficacy, implementation, and cost-effectiveness of the CATSystem to improve rates of screening, treatment, referral, and follow-up care in a matched, cluster randomized controlled trial in 10 Kenyan government hospitals (5 intervention, 5 standard of care).

Detailed Description

To help address system level barriers to cervical cancer screening, treatment, and follow-up in Kenya, investigators worked with end-users (providers and patients) to develop the Cancer Tracking System (CATSystem), a web-based, algorithm generated tool to promote guideline adherent cervical cancer screening and retention through treatment. The goal of this project is to rigorously evaluate the efficacy, implementation, and cost-effectiveness of the CATSystem to improve rates of screening, treatment, referral, and follow-up care in a matched, cluster randomized controlled trial in 10 Kenyan government hospitals (5 intervention, 5 standard of care). Specific aims (SA) of the study are to (1) Implement and evaluate the efficacy of CATSystem to improve guideline adherent cervical cancer screening, treatment, referral and follow up, (2) Assess feasibility and acceptability of implementation of CATSystem in government run facilities using a human centered design approach, and (3) Calculate the costs and cost-effectiveness of the CATSystem to increase quality adjusted life years gained. Cervical cancer deaths can be prevented with early detection and treatment. This study will evaluate the public health impact of the CATSystem in improving cervical cancer screening, treatment, referral, follow-up, and the feasibility of scale up to other low resource settings.

Registry
clinicaltrials.gov
Start Date
February 5, 2024
End Date
August 31, 2028
Last Updated
last month
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • women above 16 years of age
  • access to a cell phone,
  • presenting for cervical cancer screening at a study hospital.

Exclusion Criteria

  • greater than 20 weeks gestation,
  • incarcerated patients,
  • women who study staff feel are unable to provide written informed consent due to impaired capacity.

Arms & Interventions

CATSystem Intervention

Participants enrolled at intervention sites will receive CATSytem-supported cervical cancer screening and treatment services. Interventions received will include: text messages to patients and algorithm-driven alerts to providers when guideline-adherent cervical cancer screening and treatment services are required including: initial and follow up cervical cancer screening, on site treatment, and referral tracking.

Intervention: Cancer Tracking System (CATSystem)

Standard of care

Participants enrolled at control sites will receive standard of care PMTCT services, with no CATSystem tracking or follow up

Outcomes

Primary Outcomes

Guideline adherent treatment for a positive screen

Time Frame: 0-12 months [from screening result to treatment completion]

Provide guideline adherent treatment and rescreening for the range of possible positive screen results: cervicitis, precancerous lesions (mild, moderate, severe), invasive cervical cancer. Participants who receive the guideline adherent treatment for their positive screen result will be coded as 1 or "yes". Participants who do not receive the guideline adherent treatment for their positive screen will be coded as 0 or "no".

Secondary Outcomes

  • Cervical cancer screening(0-24 months)

Study Sites (10)

Loading locations...

Similar Trials